EGFR and neoplasm: Our study indicates that TEVs produced following IL-1β signaling activation, as well as those from both sensitive and resistant EGFR TKI-treated cells, contribute not only to tumor progression, through enhanced cell migration and EMT modulation, but also to the alterations in immune cell populations, potentially facilitating immune evasion.